Starting Aripiprazole and Cross-Tapering Risperidone in a 12-Year-Old
Start aripiprazole at 2 mg daily and gradually cross-taper the risperidone over 1-2 weeks while titrating aripiprazole to a target dose of 10 mg/day. This approach minimizes the risk of symptom destabilization while reducing the period of dual antipsychotic exposure.
Starting Dose of Aripiprazole
The FDA-approved starting dose for adolescents (13-17 years) with schizophrenia is 2 mg daily, titrated to 5 mg after 2 days, then to the target dose of 10 mg after 2 additional days 1. For a 12-year-old, this same conservative approach is appropriate, though technically off-label for this exact age. The 10 mg/day target dose has been shown to be as effective as 30 mg/day in adolescents, without additional benefit at higher doses 1.
Key dosing considerations:
- Initial: 2 mg/day
- Day 3: Increase to 5 mg/day
- Day 5-7: Increase to target 10 mg/day
- Subsequent increases (if needed): 5 mg increments, no more frequently than weekly
- Maximum studied dose: 30 mg/day (though 10 mg is typically sufficient) 2, 3
Aripiprazole can be given without regard to meals 1.
Cross-Tapering Strategy
The FDA label explicitly states that while immediate discontinuation of the previous antipsychotic may be acceptable for some patients, more gradual discontinuation may be most appropriate for others, and the period of overlapping antipsychotic administration should be minimized 1.
Recommended Cross-Taper Approach:
Week 1:
- Start aripiprazole 2 mg daily
- Maintain current risperidone dose
- After 2-3 days, increase aripiprazole to 5 mg
- Begin reducing risperidone by 25-50% of current dose
Week 2:
- Increase aripiprazole to 10 mg (target dose)
- Continue tapering risperidone by another 25-50%
Week 3 (if needed):
- Complete risperidone discontinuation
- Continue aripiprazole 10 mg monotherapy
This gradual approach is supported by research showing that both titrated-dose and fixed-dose switching strategies from risperidone to aripiprazole are safe and effective 4. The study found similar discontinuation rates due to adverse events (3.5% vs 5.0%) between approaches, with improvements in symptom scores in both groups.
Critical Monitoring Points
Extrapyramidal symptoms (EPS): Risperidone is the atypical antipsychotic most likely to cause EPS 5, particularly at doses ≥2 mg/day 6. Aripiprazole has a lower EPS risk 7, but monitor closely during the transition. If the patient was on anticholinergic medication for risperidone-induced EPS, maintain it well after risperidone discontinuation to prevent delayed emergence of symptoms 8.
Metabolic effects: Both medications can cause weight gain, but the profile differs. Monitor weight, glucose, and lipids at baseline and regularly during treatment 5.
Akathisia: Aripiprazole can cause akathisia, particularly during initial titration. This is dose-dependent and may require dose reduction 7, 3.
Sedation changes: Risperidone tends to be more sedating than aripiprazole. Patients may experience initial activation or insomnia when switching 3.
Common Pitfalls to Avoid
Too rapid discontinuation of risperidone: This increases relapse risk. The 1-2 week overlap allows aripiprazole to reach therapeutic levels while maintaining symptom control.
Starting aripiprazole too high: The 2 mg starting dose is critical for tolerability in adolescents. Higher starting doses increase akathisia risk 2.
Premature discontinuation of anticholinergics: If the patient is on benztropine or similar agents for EPS, continue these during the cross-taper and for at least 1-2 weeks after risperidone discontinuation 8.
Inadequate monitoring period: Assess response at 2-week intervals initially, as steady-state takes approximately 14 days 1.
Overlooking CYP2D6 status: If the patient is a known CYP2D6 poor metabolizer, start with half the usual aripiprazole dose 1.
Rationale for This Approach
The gradual cross-taper balances several competing priorities:
- Minimizing dual antipsychotic exposure (which lacks evidence for improved efficacy and increases side effect burden) 1
- Preventing symptom destabilization during the switch
- Allowing adequate time for aripiprazole titration to therapeutic levels
- Reducing withdrawal effects from risperidone discontinuation
Research in adults switching from risperidone to aripiprazole demonstrates that both gradual titration and more rapid fixed-dose strategies are effective and well-tolerated 4. Given the patient's age and the importance of maintaining stability, the conservative gradual approach is preferred.
The 10 mg target dose is evidence-based for adolescents with schizophrenia, showing equivalent efficacy to 30 mg with better tolerability 1, 3. In pediatric bipolar disorder studies, 10 mg/day demonstrated superior efficacy to placebo with acceptable tolerability over 30 weeks 3.